

Company Overview

CollPlant (NASDAQ:CLGN) is a regenerative medicine company focused on developing and commercializing BioInks for 3D bioprinting and tissue repair products. CollPlant's products are based on its recombinant human collagen (rhCollagen) which is produced in genetically engineered tobacco plants using CollPlant's proprietary technology. CollPlant recently entered a licensing deal with United Therapeutics, a \$5B company, for its BioInk technology to make 3D bioprinted lungs for transplantation. The Company's products, which address 3D bioprinting, medical aesthetics, orthopedics and advanced wound care, are ushering in a new era in regenerative medicine. Commercialization of CollPlant's three lead products including BioInk, VergenixSTR for tendon repair, and VergenixFG for wound care, was initiated in 2017. They address multi-billion dollar markets worldwide.

EQUITY OVERVIEW (as of 10/24/2018)

NASDAQ:CLGN

Stock Price: \$6.00

Trading Volume (90 day avg.): ~ 50,000

Shares Outstanding: ~ 3.8 M

Market Cap: ~ \$21.5 M

3D BIOPRINTING



MARKETS

Regenerative Medicine

3D Bioprinting of life saving transplants, tissues, scaffolds



Orthobiologics

Wound Care

Aesthetics



Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of CollPlant Holdings Ltd.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Investment Highlights

Using the Tobacco Plant to Produce True Human Collagen

CollPlant's technology is the only commercially viable technology currently available to produce true Type I human collagen. Collagen is an essential building block of the human body, providing structural support and biological signals to connective tissues and organs, and therefore it is a crucial component for tissue regeneration. CollPlant's proprietary technology includes the introduction into tobacco plants, of 5 human genes that are essential for the synthesis of Type I collagen. The tobacco plant then proceeds to yield human collagen that is superior to the collagen(s) currently in the market, sourced from animals, or even human cadavers. rhCollagen is identical to natural human collagen, therefore it does not elicit an immune response in humans. Its plant origin yields a safe product with more consistent properties, making it the ideal building block/scaffolding molecule for regenerative medicine. CollPlant's rhCollagen is a broadly applicable technology platform that is cost effective and enables products for medical uses with superior biological and physical properties.

3D Organ Bioprinting Leads to Deal with United Therapeutics

Recently, 3D bioprinting has been gaining momentum in many medicinal applications to address the need for complex scaffolds needed for generation of tissues and organs suitable for transplantation. CollPlant's rhCollagen-based BioInks are ideal for 3D bioprinting due to their safety profile, as well as their biological and physical properties. rhCollagen enables an unlimited, economical supply of organs around the world. Currently, 3D bioprinting is primarily used in R&D, as the technology is moving towards commercialization of manufactured lifesaving organs including lungs, liver, kidney and heart. United Therapeutics (UTHR), a leader in the field, has entered a licensing agreement with CollPlant, valued at up to \$44 M plus royalties, for use of CollPlant's BioInks for the manufacture of lungs. The ability to manufacture organs could save nearly a million lives in the U.S. alone, where 30,000 organ transplants are done each year and 900,000 people die every year due to organ impairment.

Products in Wound Care and Orthobiologics Target \$5B Market

CollPlant serves the \$6.7 B orthobiologics market with its soft tissue repair product, VergenixSTR. The product is designed for the treatment of tendinopathy, accounting for over 3 million procedures per year in the US alone. Advanced wound care treatment is a \$6.2 B market which CollPlant serves through its VergenixFG product, a wound filler for acute and chronic wounds. The size of the target market for Vergenix products is approximately \$5 B. Both products were recently launched in Europe and CollPlant is currently working on filing for FDA approval in the U.S. CollPlant's revenues from BioInk and Vergenix products for the first six months of 2018 were approximately \$400,000.

Next-Generation Dermal Filler for Aesthetic Medicine Market

CollPlant is developing a next-generation regenerative dermal filler for the multi-billion dollar medical aesthetics market. CollPlant's product combines the advantages of rhCollagen, which promotes tissue regeneration, with hyaluronic acid, which is widely used in dermal fillers today. The Company recently filed a patent application in the U.S. for photocurable dermal fillers comprised of rhCollagen and hyaluronic acid, and is actively pursuing collaborations with key companies in this field.